DigitalDx Ventures

OXcan is a startup that focuses on early detection of lung cancer using advanced machine learning and liquid biopsy technologies. The company has developed an artificial intelligence-based healthcare platform that identifies cancer by analyzing targeted blood tests. This platform detects cancer-related materials released into the bloodstream, allowing for cost-effective and routine screening. By evaluating multidimensional liquid biopsy results, which include DNA, proteins, epigenetic markers, and patient medical histories, OXcan enables healthcare providers to achieve early cancer detection and implement curative treatment strategies.

NOWDiagnostics, Inc. is a company based in Springdale, Arkansas, that specializes in the development and manufacturing of blood-based rapid diagnostic tests. Founded in 2013, the company offers innovative testing solutions that require only a single drop of blood, providing results within minutes. This approach empowers both patients and caregivers by enabling timely decision-making regarding healthcare. NOWDiagnostics' product line, ADEXUSDx, includes tests for various conditions such as pregnancy, cardiac events, and toxicology, all designed to be conducted in-home or in-clinic without the need for off-site laboratory processing. The company aims to reduce the waiting time for test results, enhancing the overall efficiency of medical diagnostics. NOWDiagnostics collaborates with strategic partners, including Zalgen Labs LLC, to expand its offerings in the diagnostic market.

Biotia, Inc. is a health technology company based in New York, founded in 2016. It specializes in developing software and laboratory technologies that leverage next-generation DNA sequencing and artificial intelligence to enhance infectious disease discovery and management. By providing tailored microbial surveillance, Biotia's innovative solutions enable clinicians and researchers to identify and mitigate pathogens effectively, thereby reducing hospital-acquired infections and improving patient outcomes. The company's technology empowers healthcare professionals to guide treatment decisions proactively, ultimately aiming to prevent illnesses before they occur.

GLX Analytix is a biotechnology company focused on transforming healthcare through the integration of proprietary blood biomarkers and artificial intelligence. The company aims to facilitate early diagnosis and continuous monitoring of chronic diseases, thereby empowering patients to manage their health more effectively. By providing tools that enable clinicians to monitor disease progression and predict flare-ups, GLX Analytix enhances treatment plans and improves patient outcomes. As an Industrial Partner to Harvard Medical/Wyss Diagnostic Accelerator and a recipient of the Roche Future of Healthcare Award, GLX Analytix is recognized for its potential to significantly impact patient care and quality of life on a global scale.

Trayt, Inc. is a patient-centric data analytics company based in Redwood City, California, focused on enhancing healthcare for patients with neuropsychiatric conditions. Founded in 2013, Trayt develops enterprise software tools that enable therapists and healthcare providers to measure the efficacy of treatments. The platform collects and analyzes a wide range of symptoms and health factors, providing real-time clinical insights that improve diagnosis and treatment accuracy. By facilitating the tracking, measurement, and sharing of behavioral and medical outcomes, Trayt aims to support clinicians in delivering coordinated and effective care.

Optina Diagnostics Inc. is a Canadian company focused on developing innovative technology for the early detection of Alzheimer’s disease through hyperspectral imaging of the eye. Founded in 2010 and headquartered in Montréal, the company employs advanced retinal imaging and artificial intelligence to provide non-invasive diagnostic tests for under-diagnosed diseases. Optina Diagnostics' retinal imaging test identifies key patient features that assist healthcare professionals in evaluating health status and disease risk, enabling timely and appropriate care. The company's imaging systems not only facilitate the detection of Alzheimer's-related biomarkers, such as beta-amyloid plaques, but also address other conditions like age-related macular degeneration and diabetic retinopathy. By enhancing brain health assessment, Optina Diagnostics aims to deliver critical information early in the disease progression, ultimately improving patient outcomes.

NephroSant is an innovative diagnostic startup established by a team of physicians and experts in science, engineering, and clinical research, dedicated to enhancing global kidney health. The company has developed a urine-based diagnostic tool that enables the quantitative measurement of biomarkers crucial for the early detection and ongoing monitoring of kidney disease. This noninvasive tool is particularly valuable for physicians, as it aids in predicting and preventing the progression of kidney disease and facilitates the early detection of acute rejection in kidney transplant patients. Through their research-driven approach, NephroSant aims to significantly improve patient outcomes in kidney health.

Trayt, Inc. is a patient-centric data analytics company based in Redwood City, California, focused on enhancing healthcare for patients with neuropsychiatric conditions. Founded in 2013, Trayt develops enterprise software tools that enable therapists and healthcare providers to measure the efficacy of treatments. The platform collects and analyzes a wide range of symptoms and health factors, providing real-time clinical insights that improve diagnosis and treatment accuracy. By facilitating the tracking, measurement, and sharing of behavioral and medical outcomes, Trayt aims to support clinicians in delivering coordinated and effective care.

Delphi Diagnostics is a biotechnology company focused on the diagnosis and management of breast cancer. It specializes in developing a gene expression interpretive algorithm that assesses the sensitivity of patients with hormone receptor positive HER2 negative breast cancer to endocrine therapy. By providing diagnostic and predictive testing services, Delphi Diagnostics aims to enhance patient outcomes by maximizing disease-free survival, reducing treatment-related toxicity, and preventing the administration of non-beneficial therapies. The company’s innovative approach supports patients, clinicians, and healthcare systems in making informed treatment decisions tailored to individual patient needs.

AEENA Dx is a biotechnology company focused on developing a saliva-based platform for the detection of cancer and other diseases. The company specializes in biofluid-based molecular diagnostic tests that aim to enhance breast cancer screening and diagnosis. By improving the sensitivity and specificity of existing mammography programs, AEENA Dx seeks to make breast cancer detection more accurate, accessible, and affordable for women. This innovative approach allows patients to easily identify potential health issues related to breast cancer, enabling them to take timely measures for prevention and treatment.

Optina Diagnostics Inc. is a Canadian company focused on developing innovative technology for the early detection of Alzheimer’s disease through hyperspectral imaging of the eye. Founded in 2010 and headquartered in Montréal, the company employs advanced retinal imaging and artificial intelligence to provide non-invasive diagnostic tests for under-diagnosed diseases. Optina Diagnostics' retinal imaging test identifies key patient features that assist healthcare professionals in evaluating health status and disease risk, enabling timely and appropriate care. The company's imaging systems not only facilitate the detection of Alzheimer's-related biomarkers, such as beta-amyloid plaques, but also address other conditions like age-related macular degeneration and diabetic retinopathy. By enhancing brain health assessment, Optina Diagnostics aims to deliver critical information early in the disease progression, ultimately improving patient outcomes.